Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

References

• Carls G, Huynh J, Tuttle E, et al. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8:863–873.
   PubMed Web of Science ®Google Scholar
• Shahraz S, Pittas AG, Saadati M, et al. Change in testing, awareness of hemoglobin a1c result, and glycemic control in US adults, 2007–2014. JAMA. 2017;318:1825–1827.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2020 abridged for primary care providers. Clin Diabetes. 2020;38:10–38.
   PubMedGoogle Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S98–S110. 9.
   PubMed Web of Science ®Google Scholar
• Saheb Kashaf M, McGill ET, Berger ZD, et al. Shared decision-making and outcomes in type 2 diabetes: a systematic review and meta-analysis. Patient Educ Couns. 2017;100:2159–2171.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Okemah J, O’Neill PM, et al. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36:44–58.
   PubMed Web of Science ®Google Scholar
• Franz MJ, Boucher JL, Rutten R, et al. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115:1447–1463.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26:107–139.
   PubMed Web of Science ®Google Scholar
• McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5:e35–48.
   PubMedGoogle Scholar
• Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410–1418.
   PubMed Web of Science ®Google Scholar
• Food and drug administration [internet]. JANUVIA® highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021995s019lbl.pdf
   Google Scholar
• Food and drug administration [internet]. ONGLYZA® highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf
   Google Scholar
• Food and drug administration [internet]. TRADJENTA® highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201280s005lbl.pdf
   Google Scholar
• Food and drug administration [internet]. ADLYXIN® highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf
   Google Scholar
• Food and drug administration [internet]. BYDUREON® BCISE^TM highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209210s000lbl.pdf.
   Google Scholar
• Food and drug administration [internet]. BYETTA® highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf
   Google Scholar
• Food and drug administration [internet]. OZEMPIC® highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
   Google Scholar
• Food and drug administration. RYBELSUS® highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
   Google Scholar
• Food and drug administration [internet]. TRULICITY® highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s007s008lbl.pdf
   Google Scholar
• Food and drug administration [internet]. VICTOZA® highlights of prescribing information, [ cited 2020 Aug 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf
   Google Scholar
• Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1975;305:14–16.
   Google Scholar
• Hædersdal S, Lund A, Knop FK, et al. The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clin Proc. 2018;93:217–239.
   PubMed Web of Science ®Google Scholar
• Holst JJ. The incretin system in healthy humans: the role of GIP and GLP-1. Metabolism. 2019;96:46–55.
   PubMed Web of Science ®Google Scholar
• Seino Y, Fukushima M, Yabe D, et al. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1:8–23.
   PubMed Web of Science ®Google Scholar
• Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–E988.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239–1246.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4:525–536.
   PubMed Web of Science ®Google Scholar
• Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326:1316–1322.
   PubMed Web of Science ®Google Scholar
• Gutniak MK, Svartberg J, Hellström PM, et al. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med. 2001;250:81–87.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Schreiber E, Fogel H, et al. Insulinotropic action of glucagon like peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care. 1992;15:270–276.
   PubMed Web of Science ®Google Scholar
• Rachman J, Barrow BA, Levy JC, et al. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205–211.
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830.
   PubMed Web of Science ®Google Scholar
• Ahrén B. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. J Diabetes Investig. 2019;10:196–201.
   PubMed Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE, et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829–835.
   PubMedGoogle Scholar
• Vilsbøll T, Agersø H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88:220–224.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features. Clin Drug Investig. 2019;39:805–819. Published corrections appear in: Clin Drug Investig. 2019;39:915–916; Clin Drug Investig. 2019;39:1019 and Clin Drug Investig. 2020;40:291.
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58:7370–7380.
   PubMed Web of Science ®Google Scholar
• van Bloemendaal L, Ten Kulve JS, la Fleur SE, et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014 7;221:T1–T16.
   PubMed Web of Science ®Google Scholar
• Gibbons C, Blundell J, Hoff ST, et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2020. Nov 12. DOI:https://doi.org/10.1111/dom.14255.
   PubMed Web of Science ®Google Scholar
• Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3:e001986.2013.
   Web of Science ®Google Scholar
• Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110:26–37.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.
   PubMed Web of Science ®Google Scholar
• Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473–4488.
   PubMed Web of Science ®Google Scholar
• Sposito AC, Berwanger O, LSF DC, et al. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17:157.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15–30.
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849–870.
   PubMed Web of Science ®Google Scholar
• Yamada H, Tanaka A, Kusunose K, et al. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc Diabetol. 2017;16:63.
   PubMed Web of Science ®Google Scholar
• Vella A. Mechanism of action of DPP-4 inhibitors–new insights. J Clin Endocrinol Metab. 2012;97:2626–2628.
   PubMed Web of Science ®Google Scholar
• Vella A, Bock G, Giesler PD, et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf). 2008;69:737–744.
   PubMed Web of Science ®Google Scholar
• Yazbeck R, Jaenisch SE, Abbott CA, et al. Dipeptidyl peptidase 4 inhibitors: applications in innate immunity?. Biochem Pharmacol. 2021;114517. DOI:https://doi.org/10.1016/j.bcp.2021.114517.
   PubMed Web of Science ®Google Scholar
• Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19:524–536.
   PubMed Web of Science ®Google Scholar
• Waldrop G, Zhong J, Peters M, et al. Incretin-based therapy in type 2 diabetes: an evidence based systematic review and meta-analysis. J Diabetes Complications. 2018;32:113–122.
   PubMed Web of Science ®Google Scholar
• Hussein H, Zaccardi F, Khunti K, et al. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabetes Obes Metab. 2020;22:1035–1046.
   PubMed Web of Science ®Google Scholar
• Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol (Lausanne). 2020;11:178.
   PubMed Web of Science ®Google Scholar
• Craddy P, Palin H-J, Johnson KI, et al. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014;5:1–41.
   PubMed Web of Science ®Google Scholar
• Bergenstal R, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431–439.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447–1456.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Masmiquel L, Kumaret H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341–354.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321:1466–1480.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:528–539.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012;34:1247–1258. e22.
   PubMed Web of Science ®Google Scholar
• Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68:557–567.
   PubMed Web of Science ®Google Scholar
• Inoue TH, Tamaki Y, Kashihara Y, et al. Efficacy of DPP‐4 inhibitors, GLP‐1 analogues, and SGLT2 inhibitors as add‐ons to metformin monotherapy in T2DM patients: a model‐based meta‐analysis. Br J Clin Pharmacol. 2019;85:393–402.
   PubMed Web of Science ®Google Scholar
• Maloney A, Rosenstock R, Fonseca V, et al. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019;105:1213–1223.
   PubMed Web of Science ®Google Scholar
• Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17:849–858.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35:252–258.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Vetter ML, Iqbal N, et al. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017;19:979–988. Published correction appears in Diabetes Obes Metab. 2017;19:1332.
   PubMed Web of Science ®Google Scholar
• Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149–2158.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–851.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42:1724–1732.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Blicher TM, Rosenlund S, et al. PIONEER 5 investigators. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515–527.
   PubMed Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394:39–50.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42:2272–2281.
   PubMed Web of Science ®Google Scholar
• Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42: 2262–2271. Published corrections appear in Lancet Diabetes Endocrinol. 2019;7:e5; Lancet Diabetes Endocrinol. 2019;7:e20 and Lancet Diabetes Endocrinol. 2019;7:e22.
   PubMed Web of Science ®Google Scholar
• Thethi T, Pratley R, Meier JJ, et al. Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020;1263–1277. DOI:https://doi.org/10.1111/dom.14054.
   PubMed Web of Science ®Google Scholar
• Li Q, Ganguly R, Ganz ML, et al. Real-world clinical effectiveness and cost savings of liraglutide versus sitagliptin in treating type 2 diabetes for 1 and 2 years. Diabetes Ther. 2018;9:1279–1293.
   PubMed Web of Science ®Google Scholar
• Dang-Tan T, Kamble PS, Meah Y, et al. Real-world effectiveness of liraglutide vs. sitagliptin among older patients with type 2 diabetes enrolled in a Medicare Advantage Prescription Drug Plan: retrospective observational study. Diabetes Ther. 2020;11:213–228.
   PubMed Web of Science ®Google Scholar
• Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28:705–714.
   PubMed Web of Science ®Google Scholar
• Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397–407.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35:1986–1993.
   PubMed Web of Science ®Google Scholar
• Bailey TS, Takács R, Tinahones FJ, et al. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes Obes Metab. 2016;18:1191–1198.
   PubMed Web of Science ®Google Scholar
• Buse JB, Bode BW, Mertens A, et al. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. BMJ Open Diabetes Res Care. 2020;8:e001649.
   PubMed Web of Science ®Google Scholar
• Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105–113.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–130.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–1529.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139:351–361.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69–79.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022–2031.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [internet]. A heart disease study of semaglutide in patients with type 2 diabetes (SOUL), [ cited 2020 Aug 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT03914326.
   Google Scholar
• Alfayez OM, Almutairi AR, Aldosari A, et al. Update on cardiovascular safety of incretin-based therapy in adults with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcome trials. Can J Diabetes. 2019;43:538–545. e2.
   PubMed Web of Science ®Google Scholar
• Fei Y, Tsoi M-F, Cheung BMY, et al. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019;18:112.
   PubMed Web of Science ®Google Scholar
• Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8–16.
   PubMed Web of Science ®Google Scholar
• Wu S, Cipriani A, Yang Z, et al. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis. Expert Opin Drug Saf. 2018;17:243–249.
   PubMed Web of Science ®Google Scholar
• Yang CT, Yang CY, Ou HT, et al. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. 2020;19:83.
   PubMed Web of Science ®Google Scholar
• Thein D, Christiansen MN, Mogensen UM, et al. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovasc Diabetol. 2020;19:107.
   PubMed Web of Science ®Google Scholar
• Longato E, Di Camillo B, Sparacino G, et al. Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice. Cardiovasc Diabetol. 2020;19:74.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Panagiotopoulou TV, Elisaf MS, et al. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11:202–230.
   PubMedGoogle Scholar
• Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004;20:411–417.
   PubMed Web of Science ®Google Scholar
• Gokhale M, Dusetzina SB, Pate V, et al. Decreased antihyperglycemic drug use driven by high out-of-pocket costs despite Medicare coverage gap closure. Diabetes Care. 2020;43:2121–2127.
   PubMed Web of Science ®Google Scholar
• Kang H, Lobo JM, Kim S, et al. Cost-related medication non-adherence among U.S. adults with diabetes. Diabetes Res Clin Pract. 2018;143:24–33.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Herman WH. The cost of diabetes care-an elephant in the room. Diabetes Care. 2018;41:929–932.
   PubMed Web of Science ®Google Scholar
• Weiss T, Iglay K, Carr RD, et al. Real-world adherence and discontinuation of GLP-1 receptor agonist (GLP-1RA) therapy in type 2 diabetes (T2D) patients in the U.S. Diabetes. 2019;68(Suppl 1). Abstract 984–P.
   PubMed Web of Science ®Google Scholar
• Nguyen H, Dufour R, Caldwell-Tarr A, et al. Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a medicare population. Adv Ther. 2017;34:658–673.
   PubMed Web of Science ®Google Scholar